Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

In 4 Starfolio Baskets

Download real time

1682.00 -10.80 (-0.64%)

Near 52W High of ₹1740.00

447.7K

NSE+BSE Volume

NSE 07 Oct, 2026 3:51 PM (IST)

US FDA Approval

Aurobindo receives US FDA nod to manufacture & market Perampanel tablets, targeting a $67 mn market See details

Aurobindo Pharma Earnings/Conference Calls

Aurobindo Pharma earnings concalls and investor presentations

Is Aurobindo Pharma Ltd. worth buying?

1269 Votes:

Buy 80.3%

Sell 13.71%

Hold 5.99%

RESEARCH REPORTS

Accumulate SEE REPORTS >

Buy SEE REPORTS >